Quick Answer
Editas Medicine, Inc. reported Operating Income Loss of -$160.01 million for the year ending 2025.
- Editas Medicine, Inc. showed an increase of +36.3% in Operating Income Loss from 2024 to 2025.
- This data is from Editas Medicine, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Editas Medicine, Inc.'s Operating Income Loss has declined by 1,157.6%.
- Historical annual values: Fiscal year 2025: -$160.01 million | Fiscal year 2024: -$251.15 million | Fiscal year 2023: -$169.18 million | Fiscal year 2022: -$225.95 million | Fiscal year 2021: -$193.15 million | Fiscal year 2020: -$134.84 million | Fiscal year 2019: -$140.92 million | Fiscal year 2018: -$113.73 million | Fiscal year 2017: -$119.93 million | Fiscal year 2016: -$97.19 million | Fiscal year 2015: -$35.31 million | Fiscal year 2014: -$12.72 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: